Key facts
- This page summarizes Sabina Rizvi's Form 4 filing for MusclePharm Corp.
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 28 Jul 2022, 16:17.
Sabina Rizvi - 21 Dec 2021 Form 4 Insider Report for MusclePharm Corp
- Reporting relationship
- President & CFO, Director
- Issuer ticker
- N/A
- Reported as of
- 21 Dec 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Jul 2022, 16:17:42 UTC
- Prior SEC filing
- 28 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sabina Rizvi
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sabina Rizvi filed Form 4 for MusclePharm Corp on 28 Jul 2022.
Change
- Previous filing in this sequence was filed on 28 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MSLP
transaction
Derivative
Options (right to buy)
Award
- Transaction value
- $0
- Shares
- +1,811,000
- Change %
- Price
- $0.000000
- Shares after
- 1,811,000
- Date
- 21 Dec 2021
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 1,811,000
- Exercise price
- $0.4000
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Options were granted pursuant to MusclePharm Corporation's 2021 Omnibus Equity Incentive Plan and vested fully on April 1, 2022.